Literature DB >> 8551237

Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55).

H Stoiber1, C Pintér, A G Siccardi, A Clivio, M P Dierich.   

Abstract

Activation of the human complement system leads to complement deposition on human immunodeficiency virus (HIV) and HIV-infected cells without causing efficient complement-mediated lysis. Even in the presence of HIV-specific antibodies, only a few particles are destroyed, demonstrating that HIV is intrinsically resistant to human complement. Here we report that, in addition to decay accelerating factor (DAF) being partially responsible, human complement factor H (CFH), a humoral negative regulator of complement activation, is most critical for this resistance. In the presence of HIV-specific antibodies, sera devoid of CFH (total genetic deficiency or normal human serum depleted of CFH by affinity chromatography) lysed free virus and HIV-infected but not uninfected cells. In the presence of CFH, lysis of HIV was only obtained when binding of CFH to gp41 was inhibited by a monoclonal antibody against a main CFH-binding site in gp41. Since CFH is an abundant protein in serum, and high local concentration of CFH can be obtained at the surface of HIV as the result of specific interactions of CFH with the HIV envelope, it is proposed that the resistance of HIV and HIV-infected cells against complement-mediated lysis in vivo is dependent on DAF and CFH and can be overcome by suppressing this protection. Neutralization of HIV may be achieved by antibodies against DAF and, more importantly, antibodies against CFH-binding sites on HIV envelope proteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8551237      PMCID: PMC2192395          DOI: 10.1084/jem.183.1.307

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

1.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

Authors:  T Muster; R Guinea; A Trkola; M Purtscher; A Klima; F Steindl; P Palese; H Katinger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

2.  Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1.

Authors:  H Stoiber; C Ebenbichler; R Schneider; J Janatova; M P Dierich
Journal:  AIDS       Date:  1995-01       Impact factor: 4.177

3.  The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum.

Authors:  B Banapour; J Sernatinger; J A Levy
Journal:  Virology       Date:  1986-07-15       Impact factor: 3.616

4.  Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1.

Authors:  H Stoiber; R Schneider; J Janatova; M P Dierich
Journal:  Immunobiology       Date:  1995-06       Impact factor: 3.144

5.  The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology.

Authors:  H Stoiber; N M Thielens; C Ebenbichler; G J Arlaud; M P Dierich
Journal:  Eur J Immunol       Date:  1994-02       Impact factor: 5.532

6.  Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120.

Authors:  C Pintér; A G Siccardi; R Longhi; A Clivio
Journal:  AIDS Res Hum Retroviruses       Date:  1995-05       Impact factor: 2.205

7.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

8.  HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology.

Authors:  C Pintér; A G Siccardi; L Lopalco; R Longhi; A Clivio
Journal:  AIDS Res Hum Retroviruses       Date:  1995-08       Impact factor: 2.205

9.  Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.

Authors:  M Saifuddin; C J Parker; M E Peeples; M K Gorny; S Zolla-Pazner; M Ghassemi; I A Rooney; J P Atkinson; G T Spear
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

10.  Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more
  47 in total

1.  Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation.

Authors:  Y Takeuchi; S H Liong; P D Bieniasz; U Jäger; C D Porter; T Friedman; M O McClure; R A Weiss
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly.

Authors:  Anuradha Radhakrishnan; Dawn Yeo; Gaie Brown; Myint Zu Myaing; Laxmi Ravi Iyer; Roland Fleck; Boon-Huan Tan; Jim Aitken; Duangmanee Sanmun; Kai Tang; Andy Yarwood; Jacob Brink; Richard J Sugrue
Journal:  Mol Cell Proteomics       Date:  2010-06-08       Impact factor: 5.911

3.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

4.  The Trojan exosome hypothesis.

Authors:  Stephen J Gould; Amy M Booth; James E K Hildreth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-28       Impact factor: 11.205

Review 5.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

Review 6.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection.

Authors:  R Herrero; L M Real; A Rivero-Juárez; J A Pineda; Á Camacho; J Macías; M Laplana; P Konieczny; F J Márquez; J C Souto; J M Soria; I Saulle; S Lo Caputo; M Biasin; A Rivero; J Fibla; A Caruz
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

8.  A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.

Authors:  Weiguo Hu; Qigui Yu; Ningjie Hu; Daniel Byrd; Tohti Amet; Cecilia Shikuma; Bruce Shiramizu; Jose A Halperin; Xuebin Qin
Journal:  J Immunol       Date:  2009-12-02       Impact factor: 5.422

9.  Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization.

Authors:  Mohammad-Ali Jenabian; Héla Saïdi; Charlotte Charpentier; Hicham Bouhlal; Dominique Schols; Jan Balzarini; Thomas W Bell; Guido Vanham; Laurent Bélec
Journal:  AIDS Res Ther       Date:  2010-06-14       Impact factor: 2.250

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.